Safety and Effectiveness of Denileukin Diftitox‐cxdl in Patients With Relapsed/Refractory Peripheral T‐Cell Lymphoma and Cutaneous T‐Cell Lymphoma: An All‐Case Post‐Marketing Study in Japan
Cancer Reports · 2026
DOI: 10.1002/cnr2.70641 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Reports, 2026. Verfasst von Tatsuro Jo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan. Hauptthemen laut MEDLINE: Diphtheria Toxin, Interleukin-2, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eisai.
Abstract (Originalsprache)
Introduction
Denileukin diftitox (DD)‐cxdl, a fusion protein comprising diphtheria toxin fragments and human interleukin‐2, is a treatment for peripheral T‐cell lymphoma (PTCL) and cutaneous T‐cell lymphoma (CTCL). Previous trials have enrolled a limited number of patients, and there is a need to evaluate DD‐cxdl in a more diverse population, including those with different ages and treatment histories.
Methods
This observational post‐marketing study (19 May 2021 to 1 February 2024) was conducted in over 200 institutions in Japan to evaluate the safety and effectiveness of DD‐cxdl in patients with relapsed or refractory PTCL and CTCL (NCT05137847; jRCT2031220196). Patient characteristics, status of drug administration, adverse events (AEs), adverse drug reactions (ADRs), and effectiveness were assessed. Capillary leak syndrome was specified as an AE of special interest.
Results
Data from 104 patients were analyzed (PTCL: 85; CTCL: 19), including 57 male patients (54.8%). The median age was 74 (range: 20–88) years. The median number of prior chemotherapy lines was 3.5 (1.0–10.0), and approximately half (55.8%) of the patients discontinued treatment during cycle 1. Most patients experienced AEs (94.2%) and ADRs (84.6%), and the most common serious ADR was capillary leak syndrome (22.1%). Effectiveness could be assessed in 80/104 patients. The overall objective response rate was 16.3% (95% confidence interval: 8.9, 26.2), and in patients with PTCL and CTCL it was 15.4% (7.6, 26.5) and 20.0% (4.3, 48.1), respectively. Four patients (6.2%) with PTCL achieved a complete response.
Conclusions
This is the first observational study to evaluate the safety and effectiveness of DD‐cxdl in Japanese patients with relapsed or refractory PTCL and CTCL in daily clinical practice. No new safety concerns were identified. Clinicians should remain aware of the risk of capillary leak syndrome. Trail Registration: ClinicalTrials.gov identifier: NCT05137847 and Japan Registry of Clinical Trials identifier: jRCT2031220196.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
- Eisai Co., Ltd., Tokyo, Japan.
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Tatsuro Jo, Koji Izutsu
Förderung
- Eisai
Zitieren
APA
Jo, T., Matsumoto, K., Ishii, M., & Izutsu, K. (2026). Safety and Effectiveness of Denileukin Diftitox‐cxdl in Patients With Relapsed/Refractory Peripheral T‐Cell Lymphoma and Cutaneous T‐Cell Lymphoma: An All‐Case Post‐Marketing Study in Japan. Cancer Reports. https://doi.org/10.1002/cnr2.70641
Vancouver
Jo T, Matsumoto K, Ishii M, Izutsu K. Safety and Effectiveness of Denileukin Diftitox‐cxdl in Patients With Relapsed/Refractory Peripheral T‐Cell Lymphoma and Cutaneous T‐Cell Lymphoma: An All‐Case Post‐Marketing Study in Japan. Cancer Reports. 2026. doi:10.1002/cnr2.70641
BibTeX
@article{Jo2026,
author = {Jo, Tatsuro and Matsumoto, Kota and Ishii, Mika and Izutsu, Koji},
title = {Safety and Effectiveness of Denileukin Diftitox‐cxdl in Patients With Relapsed/Refractory Peripheral T‐Cell Lymphoma and Cutaneous T‐Cell Lymphoma: An All‐Case Post‐Marketing Study in Japan},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70641}
}
EUVIMED